A major oncology congress means something very different to a team supporting a Phase 2 asset than it does to a team twelve months from launch. The event is the same. The therapeutic area may be the same. But what the CI function needs to extract from it, what counts as high-priority intelligence, what gets documented with the most care, and what gets synthesized first, shifts substantially depending on where an asset sits in development.
Conference coverage programs that are anchored only to a calendar of events, without calibration to lifecycle stage, tend to collect broadly and prioritize poorly. The result is thorough documentation of what happened and limited strategic utility for the team trying to decide what to do about it. Getting the calibration right is not complicated, but it requires being deliberate about what the program is actually for at each stage.
Early development and Phase 2: scientific signals and unmet need
In early development, the most valuable intelligence at a congress is scientific and mechanistic. Which therapeutic targets are generating serious attention from the research community? What are leading KOLs saying about unmet need in the relevant indication? Are competitors presenting early data that signals an accelerated path or an unexpected pivot in strategy?
At this stage, conference intelligence feeds directly into indication strategy, target product profile development, and evidence generation planning. The primary research window at a congress, conversations with investigators and KOLs close to the science, is particularly valuable here because clinical perspectives on unmet need are often more candid in the context of a scientific meeting than in any other setting. A coverage program in Phase 2 that focuses primarily on competitor data presentations is leaving the more strategically useful intelligence largely uncaptured.
Phase 3 and pre-launch: positioning signals and commercial intelligence
As an asset moves into Phase 3 and the pre-launch window, the nature of what matters at a congress shifts toward commercial intelligence. The scientific questions are largely settled. What the program needs to understand now is how competitors are framing their data for the clinical community, which patient populations and endpoints they are leading with, what claims language they are testing at the booth and in symposia, and which KOL voices are becoming affiliated with their programs.
This is the period when conference coverage intersects most directly with counter-strategy development. Positioning decisions made in the pre-launch window are difficult to reverse once they are embedded in commercial materials and stakeholder communications. Insights from a major congress two years before launch can shape those decisions. The same congress covered without that commercial lens produces a data summary rather than a strategic input.
Post-launch: competitive response and lifecycle management
Conference coverage does not end at approval. If anything, the competitive dynamics that matter most become most active in the post-launch period. Competitors respond to your market entry, present evidence designed to protect or recover their position, and begin signaling lifecycle management moves that will affect the competitive landscape over the next several years. Label expansion signals, new subgroup analyses aimed at carving out protected patient populations, and messaging shifts calibrated to real-world experience all surface at congresses before they appear in formal communications.
A post-launch coverage program is primarily a monitoring program. The question it is designed to answer is not “what is the competitive landscape?” but “how is the competitive landscape changing, and in what direction?” That requires a different analytical orientation than the pre-launch program, and a direct connection between coverage findings and the ongoing CI monitoring function that is tracking those changes between congresses.
For a detailed look at how to structure a coverage program across all three stages, including what a well-designed pre-conference plan, onsite intelligence operation, and post-conference synthesis process look like in practice, see Sedulo’s complete guide to pharmaceutical conference coverage.